Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. (REGN) is a healthcare company (biotechnology) based in the United States. The share price is $957.90, up 0.58% on the day, which values the company at $99.09B. Price as of 17 Nov 2026, 19:10 UTC, from Yahoo Finance.

Key facts

Share price
$957.90+0.58% today
Market value
$99.09B
P/E ratio
21.2×last 12 months
Forward P/E
13.5×
Dividend yield
0.39%
Funk Score
68/100
Against its own history
About its usual priceusual price $1,012.11
200-week average
$783.9122% above

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Regeneron Pharmaceuticals, Inc. in more detail

REGN trades at 21.2× its last twelve months' earnings, 13.5× next year's expected earnings, 5.9× sales. Measured against its own history, the price is 5% below what its usual multiples would imply ($1,012.11) — about its usual price. It sits 22% above its 200-week average of $783.91.

Over the last five fiscal years Regeneron Pharmaceuticals, Inc. has compounded revenue 11.0% a year, earnings per share 6.3% a year, free cash flow 13.4% a year. Its Funk Score is 68 out of 100 (financial strength 9.1, profitability 6.6, growth 5.6, value 6.1, each out of 10).

In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Gross margin is shrinking.

10 of the superinvestors tracked here hold REGN, including Mason Hawkins (5.0% of the portfolio), Harry Burn (3.0% of the portfolio), Dodge & Cox team (1.9% of the portfolio).

Superinvestors holding REGN

10 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:REGN vs ELV (Regeneron Pharmaceuticals, Inc. vs Elevance Health)REGN vs GSK (Regeneron Pharmaceuticals, Inc. vs GSK)REGN vs HCA (Regeneron Pharmaceuticals, Inc. vs HCA Healthcare)REGN vs CVS (Regeneron Pharmaceuticals, Inc. vs CVS Health)REGN vs MRNA (Regeneron Pharmaceuticals, Inc. vs Moderna)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Regeneron Pharmaceuticals, Inc. (REGN): questions and answers

What is REGN's P/E ratio?

Regeneron Pharmaceuticals, Inc. trades at 21.2× its last twelve months' earnings and 13.5× next year's expected earnings. At its fiscal year-ends over the past 14 years the P/E ranged from 8.8× to 137.7×, with a median of 22.8×.

What is REGN's PEG ratio?

Regeneron Pharmaceuticals, Inc.'s PEG ratio is 1.16 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Regeneron Pharmaceuticals, Inc.'s market cap?

Regeneron Pharmaceuticals, Inc. is valued at $99.09B at a share price of $957.90.

Is REGN overvalued or undervalued?

Against its own history, REGN is about its usual price: the price is 5% below the $1,012.11 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is REGN above its 200-week moving average?

Yes. REGN is 22.2% above its 200-week average of $783.91. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Regeneron Pharmaceuticals, Inc. growing?

Over the last five fiscal years Regeneron Pharmaceuticals, Inc.'s revenue grew 11.0% a year and its earnings per share 6.3% a year; over ten years revenue grew 13.3% a year.

Cite this page

Funkfolio, “Regeneron Pharmaceuticals, Inc. (REGN) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/REGN

Underlying data: Yahoo Finance; company filings with the SEC.